FDA To Review Bristol-Myers Squibb Company’s New Diabetes Drug

AP -- The drug industry and investors will be carefully monitoring a government meeting Wednesday as Bristol-Myers Squibb presents a new diabetes drug to experts who have become increasingly cautious of safety risks.